FDA names former pharmaceutical company executive to oversee US drug program
FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency's Center for Drug Evaluation and Research, which regulates the safety and effectiveness of all U.S. drugs.
His appointment comes a month after the center's acting director, Dr. Jacqueline Corrigan-Curay, announced her retirement.
As the agency's top drug regulator, Tidmarsh will be charged with following through on a number of commitments made by Makary and his boss, Health Secretary Robert F. Kennedy Jr., including reviewing the safety of the abortion pill mifepristone. The FDA is also scrutinizing certain uses of other long-established drugs, including antidepressants and hormone-replacement drugs for menopause.
Tidmarsh founded and led several pharmaceutical companies, including Horizon Pharmaceuticals, maker of an anti-inflammatory medication for arthritis. He has also served as an adjunct professor at Stanford University.
The FDA's drug center is the agency's largest unit, with nearly 6,000 staffers responsible for reviewing the safety and effectiveness of new drugs and monitoring the use and marketing of older drugs.
About 2,000 FDA staffers have been laid off as part of widescale cuts to the federal health workforce overseen by Kennedy. More than 1,000 others have taken buyouts or early retirement, while many others are reportedly searching for new jobs. The departures have threatened basic FDA operations, including the timely review of new drugs.
FDA's drug center hasn't had a permanent director since January, when Dr. Patrizia Cavazzoni stepped down days before President Donald Trump took office.
Nearly all of the FDA's senior leadership positions have turned over in recent months, either due to retirements, resignations or actions by administration officials placing them on administrative leave.
FDA center directors typically hold their positions for years or even decades, serving across multiple administrations, whether Republican or Democrat.
In May, Makary named Dr. Vinay Prasad, a prominent critic of the FDA's COVID response, to run the agency's vaccine center. He was also named to the post of FDA chief medical officer. Prasad joined the agency after his predecessor, longtime vaccine chief Dr. Peter Marks, was forced out in March.
The head of FDA's tobacco center was also forced to step down in April. A permanent replacement has not yet been named.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
2 hours ago
- New York Post
Thousands of New Yorkers — including ‘Orange is the New Black' actor Matt McGorry — suffer from ‘Long COVID'
Tens of thousands of New Yorkers — including 'Orange is the New Black' actor Matt McGorry — suffer from 'long COVID' five years after the deadly once-in-a-century pandemic hit, shocking new data reveal. 'My actual daily survival is based on understanding and navigating [it],' said McGorry, a 39-year-old Manhattan native, who was part of a recent online city Department of Health series about the issue. A COVID and flu vaccination campaign conducted by the Health Department over the past year referred 21,805 residents to receive long-COVID-specific services during medical check-ups and outreach programs. Advertisement 3 'Orange is the New Block' actor Matt McGorry suffers from 'long COVID.' NYCHealth The department also is conducting an ongoing study of residents who have had COVID-19. Preliminary results from the study so far indicate that more than one in four of the adults has experienced long-term symptoms, meeting the definition for long COVID. Advertisement More than 80% of those with long COVID reported limitations in daily functioning, and more than 25% said they experienced employment changes because of related medical issues. An estimated 500,000 residents had lingering COVID-impacted illnesses that interfered with daily life in 2023, the department said. 'Together, these studies suggest that New Yorkers continue to experience the long-term effects of COVID-19, impacting not only health, but also work and daily life,' a Health Department spokesman said in a statement. 'Given the wide range and persistence of symptoms, the Health Department is continuing to analyze these data to better understand the burden of Long COVID and inform responsive public health strategies.' Advertisement 3 According to New York City Department of Health data, there are tens of thousands of New Yorkers are living with long COVID. BASILICOSTUDIO STOCK – Symptoms of long COVID include coughing or feeling short of breath, trouble thinking clearly or concentrating or having 'brain fog,' dizziness or a fast heart rate, sleep issues, anxiety or depression, fatigue, stomach problems, muscle pains or losing the ability to taste or smell. Long COVID also impacts blood vessels, raising the risk of heart ailments. Acting Health Department Commissioner Dr. Michelle Morse said long COVID is a serious problem that warrants monitoring of patients, the way the medical community has tracked the medical conditions of residents exposed to toxic fumes and debris from 9/11. Advertisement 3 'Brain fog' and having trouble concentrating is one of the symptoms of long COVID. Antonioguillem – She discussed the department's efforts during two video interviews with McGorry. 'Our data here in New York City suggests there are about one in three New Yorkers who say they had symptoms that had lasted more than a month after their COVID infection,' Morse said. Not all those cases meet the definition of long COVID, Morse said. McGorry, 39, said long COVID severely impacted his career, which has included roles in the hit Netflix series 'Orange is the New Black' and the TV series 'How to Get Away With Murder.' 'Fatigue was and still is the main issue,' he said. Every morning, the NY POSTcast offers a deep dive into the headlines with the Post's signature mix of politics, business, pop culture, true crime and everything in between. Subscribe here! He said he sometimes feels 'light-headed', has trouble sleeping and has blood vessel damage and micro-clots. Advertisement The actor said he decided to go public as part of a public-awareness and social-justice campaign to help others less well off than he is navigate lingering medical woes from the coronavirus. 'Essentially I have been locked out of my industry, and that has had big financial impacts,' McGorry told Morse. 'No one should have to choose between a paycheck and their life and safety. … I really want to raise as much awareness as possible.' Advertisement Over the past year, the department has sought to bolster COVID and flu vaccination rates in underserved neighborhoods through its Building Resiliency and Vaccine Equity program. The program reached 319,507 residents and referred 42,773 New Yorkers for COVID vaccination. Medical and social-service coordinators also referred 80,975 people to COVID-related services, and specifically 21,805 participants to long-COVID-specific services and 257,802 to other health and social services.
Business Insider
4 hours ago
- Business Insider
Sarepta says eight-year-old death deemed unrelated to Elevidys
Sarepta (SRPT) said in a statement Friday night: 'Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy patient who had received Elevidys gene therapy. The death of this patient was deemed unrelated to treatment with Elevidys…Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. Elevidys is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy.' Elevate Your Investing Strategy:
New York Post
4 hours ago
- New York Post
Breakthrough as two FDA-approved drugs are found to reverse Alzheimer's — including restoring memory
In a stunning scientific discovery, researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. And the best part of all? Both are already FDA-approved — albeit for cancer. Researchers first pinpointed how Alzheimer's disease scrambles gene activity in individual brain cells. 3 Researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. Pixel-Shot – Using the Connectivity Map database of 1,300 FDA‑approved drugs, the researchers looked for medications that reverse Alzheimer's‑associated gene expression — landing on a shortlist of five, and zeroing in on two cancer drugs. In what one researcher called a 'mock clinical trial,' they then mined 1.4 million patients' medical records, finding that those who had taken letrozole or irinotecan for cancer were significantly less likely to develop Alzheimer's. When given together in an aggressive Alzheimer's mouse model, letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Most importantly, they restored memory and learning in mice that had already developed severe symptoms. It's an exciting development for an illness that's notoriously tricky. 3 Letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Eric Hood – 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly,' Marina Sirota, the interim director of the UCSF Bakar Computational Health Sciences Institute, said in a statement. 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. 'This makes it very challenging for drug development — which traditionally produces one drug for a single gene or protein that drives disease.' 3 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. yurakrasil – The findings were published in the journal Cell. Both drugs are already FDA‑approved for other uses, which could dramatically speed up the path to human trials. However, because they are cancer drugs, repurposing them may be complex and risky. This finding adds to a growing number of potential Alzheimer's treatments. A compound found in rosemary and sage — carnosic acid — has been shown to reverse memory loss and reduce brain inflammation in mice with Alzheimer's, bringing their cognitive function back to near-normal levels. A study from Stanford Medicine found that seniors who received the shingles vaccine were 20% less likely to develop dementia over seven years. And researchers at Penn State and Stanford University discovered that a certain cancer drug could restore memory and brain function in early stage Alzheimer's models.
